These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36210555)

  • 21. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
    Covut F; Sanfilippo KM
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence of venous thromboembolism among adults acute leukemia patients treated at the University of Texas MD Anderson Cancer Center: Incidence and risk factors.
    Luong NV; Kroll MH; Vu K
    Thromb Res; 2017 Aug; 156():14-19. PubMed ID: 28577388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
    Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
    J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for inpatient venous thromboembolism despite thromboprophylaxis.
    Wang TF; Wong CA; Milligan PE; Thoelke MS; Woeltje KF; Gage BF
    Thromb Res; 2014 Jan; 133(1):25-9. PubMed ID: 24300584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.
    Annibali O; Napolitano M; Avvisati G; Siragusa S
    Crit Rev Oncol Hematol; 2018 Apr; 124():41-50. PubMed ID: 29548485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction and Prevention of Cancer-Associated Thromboembolism.
    Khorana AA; DeSancho MT; Liebman H; Rosovsky R; Connors JM; Zwicker J
    Oncologist; 2021 Jan; 26(1):e2-e7. PubMed ID: 33274815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.
    Spyropoulos AC; Eldredge JB; Anand LN; Zhang M; Qiu M; Nourabadi S; Rosenberg DJ
    Oncologist; 2020 Jul; 25(7):e1083-e1090. PubMed ID: 32017293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
    Louzada ML; Carrier M; Lazo-Langner A; Dao V; Kovacs MJ; Ramsay TO; Rodger MA; Zhang J; Lee AY; Meyer G; Wells PS
    Circulation; 2012 Jul; 126(4):448-54. PubMed ID: 22679142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of two general venous thromboembolism risk-stratification models in predicting venous thromboembolic events in TB patients.
    Sharif-Kashani B; Azimi M; Tabarsi P; Sadr M; Shirzadi S
    Int J Mycobacteriol; 2022; 11(1):83-87. PubMed ID: 35295028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.
    da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
    J Thromb Thrombolysis; 2023 Jul; 56(1):147-155. PubMed ID: 37133703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients.
    Streiff MB
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):349-57. PubMed ID: 24472803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.
    Figueroa R; Alfonso A; López-Picazo J; Gil-Bazo I; García-Mouriz A; Hermida J; Páramo JA; Lecumberri R
    PLoS One; 2018; 13(8):e0200220. PubMed ID: 30071038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
    Wiseman DN; Harrison J
    N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
    Sanfilippo KM; Wang TF; Gage BF; Luo S; Riedell P; Carson KR
    Thromb Res; 2016 Jul; 143():86-90. PubMed ID: 27208462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
    Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
    J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis.
    Zhang C; Zhang Z; Mi J; Wang X; Zou Y; Chen X; Nie Z; Luo X; Gan R
    Medicine (Baltimore); 2019 Jun; 98(23):e15833. PubMed ID: 31169685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark.
    Lund JL; Østgård LS; Prandoni P; Sørensen HT; de Nully Brown P
    Thromb Res; 2015 Nov; 136(5):917-23. PubMed ID: 26371409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.